These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19589292)

  • 1. Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis.
    Panigalli S; Coccarielli D; Germi L; Trevisan GP; Veller-Fornasa C
    J Biol Regul Homeost Agents; 2009; 23(2):111-7. PubMed ID: 19589292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis.
    De Simone C; D'Agostino M; Capizzi R; Capponi A; Venier A; Caldarola G
    Eur J Dermatol; 2011; 21(4):568-72. PubMed ID: 21697032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.
    Park KK; Wu JJ; Koo J
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):899-906. PubMed ID: 22702846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
    Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
    Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
    Wolf P; Hofer A; Legat FJ; Bretterklieber A; Weger W; Salmhofer W; Kerl H
    Br J Dermatol; 2009 Jan; 160(1):186-9. PubMed ID: 19067710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept.
    Lynde CW; Gupta AK; Guenther L; Poulin Y; Levesque A; Bissonnette R
    J Dermatolog Treat; 2012 Aug; 23(4):261-7. PubMed ID: 21797805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept.
    Shah SK; Arthur A; Yang YC; Stevens S; Alexis AF
    J Drugs Dermatol; 2011 Aug; 10(8):866-72. PubMed ID: 21818507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
    Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
    J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
    Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B
    Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
    Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
    Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe generalized exanthema due to etanercept given for severe plaque psoriasis.
    Gonzalo-Garijo MA; Pérez-Calderón R; de Argila Fernández-Durán D
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):621-2. PubMed ID: 18592833
    [No Abstract]   [Full Text] [Related]  

  • 18. A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study.
    Zane C; Capezzera R; Venturini M; Sala R; Facchinetti E; Pedretti A; Calzavara-Pinton P
    Dermatology; 2009; 218(4):321-6. PubMed ID: 19279381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
    Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.